Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07252479 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | recruiting | Phase 1 | 118 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07512583 | Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 178 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 |
| clinicaltrials |
| NCT07570563 | Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 24 | Chinese PLA General HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05232409 | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | recruiting | Phase 1 | 72 | Valley Health SystemOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | completed | Phase 1 / Phase 2 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT06894745 | PET [89Zr]DFO-starPEG in Solid Tumors | recruiting | Phase 1 | 13 | Robert Flavell, MD, PhDOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04621435 | Imaging of Solid Tumors Using FAP-2286 | recruiting | Phase 1 | 191 | Thomas HopeOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04800822 | PF-07284892 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 53 | PfizerINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05004116 | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | recruiting | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06480552 | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 240 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT07395258 | A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 60 | Boehringer IngelheimINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07077434 | A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 32 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 3, 2026 | clinicaltrials |
| NCT07086768 | Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 57 | Lei ZhengOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07593144 | A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) | not yet recruiting | Phase 1 | 156 | Foresight Therapeutics (Hefei) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622225 | SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07623707 | A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624864 | A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT04303858 | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 | 189 | Hoffmann-La RocheINDUSTRY | 5 | Jun 2, 2026 | clinicaltrials |
| NCT04796012 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06815575 | A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. | recruiting | Phase 1 | 53 | Racura Oncology LtdINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06936735 | A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 171 | SEED Therapeutics, Inc.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05571969 | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors | terminated | Phase 1 | 14 | Allarity TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618260 | SIM0613 in Participants With Advanced Solid Tumors(SIM0613-101) | recruiting | Phase 1 | 294 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04145622 | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | recruiting | Phase 1 / Phase 2 | 250 | Daiichi SankyoINDUSTRY | 2 | May 29, 2026 | clinicaltrials |
| NCT06235983 | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07615660 | Clinical Study of CVL006 Combination With 9MW2821(CVL006-T1003) | not yet recruiting | Phase 1 / Phase 2 | 108 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT07615894 | WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) | not yet recruiting | Phase 1 | 9 | WestVac Biopharma Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07404332 | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | recruiting | Phase 1 | 35 | Mohammed MilhemOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07538479 | Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)(NIVALIS) | recruiting | Phase 1 | 24 | West China HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07611370 | Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers | not yet recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612137 | Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 282 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07612488 | A Study of CS231295 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 42 | ThalassaX Therapeutics United States LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | Peter ZageOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials